LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 91

Search options

  1. Article ; Online: Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer.

    Konecny, Gottfried E

    The Lancet. Oncology

    2019  Volume 20, Issue 5, Page(s) 612–614

    MeSH term(s) Antibodies, Monoclonal, Humanized ; Endometrial Neoplasms/genetics ; Female ; Humans ; Microsatellite Repeats ; Phenylurea Compounds ; Programmed Cell Death 1 Receptor ; Quinolines ; Vascular Endothelial Growth Factor A
    Chemical Substances Antibodies, Monoclonal, Humanized ; Phenylurea Compounds ; Programmed Cell Death 1 Receptor ; Quinolines ; Vascular Endothelial Growth Factor A ; pembrolizumab (DPT0O3T46P) ; lenvatinib (EE083865G2)
    Language English
    Publishing date 2019-03-25
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(19)30079-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer.

    Konecny, Gottfried E

    EBioMedicine

    2019  Volume 43, Page(s) 9–10

    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Female ; Genes, myc ; Genetic Predisposition to Disease ; Humans ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/metabolism ; Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/administration & dosage
    Chemical Substances Poly(ADP-ribose) Polymerase Inhibitors ; Protein Kinase Inhibitors ; CDK4 protein, human (EC 2.7.11.22) ; CDK6 protein, human (EC 2.7.11.22) ; Cyclin-Dependent Kinase 4 (EC 2.7.11.22) ; Cyclin-Dependent Kinase 6 (EC 2.7.11.22)
    Language English
    Publishing date 2019-04-09
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 2851331-9
    ISSN 2352-3964
    ISSN (online) 2352-3964
    DOI 10.1016/j.ebiom.2019.04.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7090: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer.

    Konecny, Gottfried E

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2017  Volume 35, Issue 11, Page(s) 1151–1153

    MeSH term(s) Adenosine Diphosphate ; Humans ; Ovarian Neoplasms ; Poly(ADP-ribose) Polymerases ; Ribose
    Chemical Substances Adenosine Diphosphate (61D2G4IYVH) ; Ribose (681HV46001) ; Poly(ADP-ribose) Polymerases (EC 2.4.2.30)
    Language English
    Publishing date 2017-03-06
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2016.72.0052
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Cyclin-dependent kinase pathways as targets for women's cancer treatment.

    Konecny, Gottfried E

    Current opinion in obstetrics & gynecology

    2016  Volume 28, Issue 1, Page(s) 42–48

    Abstract: Purpose of review: In this article, we not only review the preclinical and clinical studies of cyclin-dependent kinase (CDK) 4/6 inhibitors in breast cancer, liposarcoma, mantel cell lymphoma, melanoma and germ cell tumors, but also examine promising ... ...

    Abstract Purpose of review: In this article, we not only review the preclinical and clinical studies of cyclin-dependent kinase (CDK) 4/6 inhibitors in breast cancer, liposarcoma, mantel cell lymphoma, melanoma and germ cell tumors, but also examine promising preclinical data in glioblastoma, renal and ovarian cancer models that may provide directions for future development.
    Recent findings: Targeting CDKs has been the focus of considerable basic science and clinical research. The CDK 4/6 inhibitors are a novel class of therapeutics that target the CDK 4/6 kinases that promote transition through the cell cycle. Currently, palbociclib (PD0332991, Pfizer), abemaciclib (LY2835219, Lilly) and ribociclib (LEE011, Novartis) are being investigated in clinical trials. These oral agents offer the hope of clinical efficacy in many tumor types, and have been associated with minimal toxicity. Amplification/overexpression of cyclin D, loss of CDKN2A (p16) and amplification/overexpression of CDK4 are proposed biomarkers of improved response to CDK4/6 inhibition.
    Summary: Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma. Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development. Further preclinical and clinical research is needed to better understand mechanisms of resistance and develop rational combination therapies with other targeted agents.
    MeSH term(s) Aminopyridines/therapeutic use ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Breast Neoplasms/drug therapy ; Cell Cycle ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Female ; Humans ; Liposarcoma/drug therapy ; Lymphoma, Mantle-Cell/drug therapy ; Melanoma/drug therapy ; Neoplasms, Germ Cell and Embryonal/drug therapy ; Piperazines/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Purines/therapeutic use ; Pyridines/therapeutic use ; Signal Transduction/drug effects
    Chemical Substances Aminopyridines ; Antineoplastic Agents ; Piperazines ; Protein Kinase Inhibitors ; Purines ; Pyridines ; Cyclin-Dependent Kinase 4 (EC 2.7.11.22) ; Cyclin-Dependent Kinase 6 (EC 2.7.11.22) ; palbociclib (G9ZF61LE7G) ; ribociclib (TK8ERE8P56)
    Language English
    Publishing date 2016-02
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1049382-7
    ISSN 1473-656X ; 1040-872X
    ISSN (online) 1473-656X
    ISSN 1040-872X
    DOI 10.1097/GCO.0000000000000243
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3048: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Cancer genomics and clinical practice: how can we close the gap more quickly?

    Konecny, Gottfried E

    Current opinion in obstetrics & gynecology

    2016  Volume 29, Issue 1, Page(s) 1–3

    MeSH term(s) Animals ; Biomedical Research/methods ; Biomedical Research/trends ; Breast Neoplasms/genetics ; Breast Neoplasms/therapy ; Drug Discovery ; Endometrial Neoplasms/genetics ; Endometrial Neoplasms/therapy ; Female ; Genomics ; Humans ; Medical Oncology/methods ; Medical Oncology/trends ; Mice ; Neoplasms/genetics ; Neoplasms/therapy ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/therapy ; Precision Medicine/methods ; Precision Medicine/trends ; Translational Medical Research/methods ; Translational Medical Research/trends ; United States
    Language English
    Publishing date 2016-12-07
    Publishing country England
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 1049382-7
    ISSN 1473-656X ; 1040-872X
    ISSN (online) 1473-656X
    ISSN 1040-872X
    DOI 10.1097/GCO.0000000000000341
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3048: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Securing global access to innovations in women's cancer care and control.

    Konecny, Gottfried E

    Current opinion in obstetrics & gynecology

    2016  Volume 28, Issue 1, Page(s) 1–3

    MeSH term(s) Developing Countries ; Early Detection of Cancer/economics ; Early Detection of Cancer/trends ; Female ; Fertility Preservation/economics ; Fertility Preservation/trends ; Genital Neoplasms, Female/diagnosis ; Genital Neoplasms, Female/prevention & control ; Genital Neoplasms, Female/therapy ; Global Health ; Humans ; Organizational Innovation ; Papillomavirus Vaccines/administration & dosage ; Quality of Health Care/organization & administration ; Urologic Neoplasms/diagnosis ; Urologic Neoplasms/prevention & control ; Urologic Neoplasms/therapy ; Women's Health Services/organization & administration
    Chemical Substances Papillomavirus Vaccines
    Language English
    Publishing date 2016-02
    Publishing country England
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 1049382-7
    ISSN 1473-656X ; 1040-872X
    ISSN (online) 1473-656X
    ISSN 1040-872X
    DOI 10.1097/GCO.0000000000000244
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3048: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: The path to personalized medicine in women's cancers: challenges and recent advances.

    Konecny, Gottfried E

    Current opinion in obstetrics & gynecology

    2015  Volume 27, Issue 1, Page(s) 45–47

    MeSH term(s) Breast Neoplasms/therapy ; Disease-Free Survival ; Female ; Fertility Preservation ; Genital Neoplasms, Female/therapy ; Humans ; Molecular Targeted Therapy/trends ; Precision Medicine/trends ; Women's Health
    Language English
    Publishing date 2015-02
    Publishing country England
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 1049382-7
    ISSN 1473-656X ; 1040-872X
    ISSN (online) 1473-656X
    ISSN 1040-872X
    DOI 10.1097/GCO.0000000000000149
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3048: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.

    Konecny, Gottfried E / Chander, Cinthiya / Zhang, Liying

    Cancer journal (Sudbury, Mass.)

    2021  Volume 27, Issue 6, Page(s) 482–490

    Abstract: Abstract: In this article, we highlight biomarkers for poly(ADP-ribose) polymerase inhibitor (PARPi) sensitivity and resistance and discuss their implications for the clinic. We review the predictive role of a range of DNA repair genes, genomic scars, ... ...

    Abstract Abstract: In this article, we highlight biomarkers for poly(ADP-ribose) polymerase inhibitor (PARPi) sensitivity and resistance and discuss their implications for the clinic. We review the predictive role of a range of DNA repair genes, genomic scars, mutational signatures, and functional assays available or in development. The biomarkers used for patient selection in the specific Food and Drug Administration-approved indications for breast, ovarian, prostate, and pancreatic cancer vary across tumor type and likely depend on disease-specific DNA repair deficiencies but also the specifics of the individual clinical trials that were conducted. Mutations in genes involved in homologous recombination and/or replication fork protection are synthetic lethal with PARPi. Cancers with homologous recombination deficiency exhibit high genomic instability, characterized by genome-wide loss of heterozygosity, among other genomic aberrations. Next-generation sequencing can identify multiple patterns of genomic changes including copy number variations, single-nucleotide variations, insertions/deletions, and structural variations rearrangements characteristic of homologous recombination deficiency. Clinical trial evidence supports the use of BRCA mutation testing for patient selection, and for ovarian cancer, there are 3 commercial assays available that additionally incorporate genomic instability for identifying subgroups of patients that derive different magnitudes of benefit from PARPi therapy. Finally, we summarize new strategies for extending the benefit of PARPi therapy toward broader populations of patients through the use of novel biomarkers. Ultimately, design of a composite biomarker test combining multiple mutational signatures or development of a dynamic assay for functional assessments of homologous recombination may help improve the test accuracy for future patient stratification.
    MeSH term(s) Biomarkers ; DNA Copy Number Variations ; Female ; Humans ; Mutation ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
    Chemical Substances Biomarkers ; Poly(ADP-ribose) Polymerase Inhibitors
    Language English
    Publishing date 2021-12-14
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2018400-1
    ISSN 1540-336X ; 1528-9117 ; 1081-4442
    ISSN (online) 1540-336X
    ISSN 1528-9117 ; 1081-4442
    DOI 10.1097/PPO.0000000000000564
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4470: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 163: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Mechanisms of PARP inhibitor resistance in ovarian cancer.

    Kubalanza, Kari / Konecny, Gottfried E

    Current opinion in obstetrics & gynecology

    2019  Volume 32, Issue 1, Page(s) 36–41

    Abstract: Purpose of review: To summarize recently discovered PARP inhibitor resistance mechanisms and highlight the clinical relevance of these findings to date.: Recent findings: A predominant mechanism of acquired PARP inhibitor resistance in homologous ... ...

    Abstract Purpose of review: To summarize recently discovered PARP inhibitor resistance mechanisms and highlight the clinical relevance of these findings to date.
    Recent findings: A predominant mechanism of acquired PARP inhibitor resistance in homologous recombination-deficient cancers is the acquisition of homologous recombination proficiency as a consequence of secondary genetic or epigenetic events, such as secondary mutations in BRCA1 or BRCA2, or reversal of BRCA1 promoter methylation that restores homologous recombination and leads to PARP inhibitor resistance. Multiple other potential mechanisms of acquired resistance to PARP inhibitors including loss of DNA end resection inhibition (53BP1/REV7/RIF1/Sheldin) or DNA replication fork protection (PTIP/EZH2), but also increased drug efflux or induction of a reversible senescent or mesenchymal cell state have been described in ovarian cancer models. However, only few of these mechanisms have been identified in clinical samples.
    Summary: Multiple adaptive responses following PARP inhibitor treatment have been identified. Further research is needed to better understand what role these mechanisms play for clinical PARP inhibitor resistance and how these mechanisms may render ovarian cancer cells susceptible to subsequent novel combination therapies.
    MeSH term(s) Animals ; BRCA1 Protein/drug effects ; BRCA2 Protein/drug effects ; Carcinoma, Ovarian Epithelial/drug therapy ; Drug Resistance, Neoplasm/drug effects ; Female ; Homologous Recombination/drug effects ; Humans ; Mice ; Ovarian Neoplasms/drug therapy ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
    Chemical Substances BRCA1 Protein ; BRCA1 protein, human ; BRCA2 Protein ; BRCA2 protein, human ; Poly(ADP-ribose) Polymerase Inhibitors
    Language English
    Publishing date 2019-12-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1049382-7
    ISSN 1473-656X ; 1040-872X
    ISSN (online) 1473-656X
    ISSN 1040-872X
    DOI 10.1097/GCO.0000000000000600
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3048: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Sequencing efforts help to refine the molecular classification of breast cancer.

    Konecny, Gottfried E

    Current opinion in obstetrics & gynecology

    2014  Volume 26, Issue 1, Page(s) 18–20

    MeSH term(s) Biomarkers, Tumor/genetics ; Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Breast Neoplasms/therapy ; DNA, Neoplasm/genetics ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Mutation ; Pathology, Molecular/methods ; Pathology, Molecular/trends ; Sequence Analysis, DNA
    Chemical Substances Biomarkers, Tumor ; DNA, Neoplasm
    Language English
    Publishing date 2014-02
    Publishing country England
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 1049382-7
    ISSN 1473-656X ; 1040-872X
    ISSN (online) 1473-656X
    ISSN 1040-872X
    DOI 10.1097/GCO.0000000000000040
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3048: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top